Chemotherapy for advanced hepatocellular carcinoma Adriamycin versus quadruple chemotherapy
Authors:
Abstract
In a prospective clinical trial, 39 patients with advanced hepatocellular carcinoma were randomized to receive either Adriamycin (20 patients) or a combination of 5-fluorouracil, methotrexate, cyclophosphamide, and vincristine (19 patients). Five patients receiving Adriamycin and none receiving quadruple chemotherapy responded (P < 0.05 in favor of Adriamycin). A further 25 patients were treated with Adriamycin, making a total of 45. The overall objective response rate was 24% (11 patients), with 3 complete remissions and 8 partial remissions. The median survival for Adriamycin-treated patients (13.0 weeks for the first 20 patients and 14.4 weeks for all patients) was longer than those treated by quadruple chemotherapy (6.5 weeks). The difference, however, was not significant by the Wilcoxan test as modified by Gehan. Patients with positive HbsAg had a significantly higher chance of having a response, while serum alpha-fetoprotein levels did not correlate with response.Keywords
This publication has 10 references indexed in Scilit:
- Further experience in treating patients with hepatocellular carcinoma in UgandaCancer, 1980
- Chemotherapy studies in primary liver cancer. A prospective randomized clinical trialCancer, 1978
- Intraarterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma.A clinical and pharmacology reportCancer, 1978
- DOXORUBICIN FOR LIVER CANCERThe Lancet, 1978
- INDUCTION OF REMISSION IN HEPATOCELLULAR CARCINOMA WITH DOXORUBICINThe Lancet, 1978
- Methods for Censored Data1977
- Quadruple chemotherapy versus radiotherapy in treatment of primary hepatocellular carcinomaCancer, 1977
- A phase II study of adriamycin (NSC 123127) in patients with hepatocellular carcinoma from Zambia and the United StatesCancer, 1977
- ADRIAMYCIN AND 5-FLUOROURACIL IN TREATMENT OF ADVANCED HEPATOMA - SOUTHWEST ONCOLOGY GROUP STUDY1977
- Treatment of hepatocellular carcinoma with adriamycin.Preliminary communicationCancer, 1975